Cardiovascular Adverse Events Associated with Bispecific T-cell Engager Therapy | JACC: CardioOncology

Dr. Qun Shao discusses two multicenter studies evaluating cardiovascular adverse events associated with bispecific T‑cell engager therapies. Drawing on data from over 700 patients, the episode highlights the incidence, predictors, and clinical impact of cardiovascular complications, emphasizing the importance of baseline risk assessment, targeted monitoring, and multidisciplinary management as use of these therapies continues to expand.